The Association of NAD(P)H:quinine Oxidoreductase Gene Polymorphisms With Pediatric Acute Lymphoblastic Leukemia

Objectives: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. NAD(P)H:quinone oxidoreductase 1 (NQO1) is an enzyme that protects cells against mutagenicity of free radicals and toxic oxygen metabolites. C to T base substitution at nucleotides 609 and 465 of NQO1 cDNA, results in loss of enzyme activity. Low NQO1 activity may play a role in etiology of ALL. In the present study, we investigated the association between the NQO1 polymorphisms and increased risk of ALL in children. Methods: C609T and C465T polymorphisms of NQO1 were explored using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) assay in 100 pediatric ALL patients and 135 healthy controls. Results: Although C609T polymorphism is very common among the Iranian population, we found no association between this variant and increased risk for pediatric ALL [odds ratio (OR) = 0.95; 95% confidence interval (95% CI) = 0.55–1.64]. Interestingly the other polymorphic allele of NQO1 (C465T) was strongly associated with pediatric ALL (OR = 7.83; 95% CI= 3.27-18.75). Conclusion: These findings do not support the predisposing role of NQO1 C609T polymorphism for pediatric ALL. However, The C465T polymorphism was associated with increased risk of pediatric ALL. Further studies with larger sample including evaluating multiple gene– gene interactions seem necessary to validate the exact role of these mutations.

[1]  F. Zaker,et al.  The Frequency and Association of C609T and C465T Polymorphisms of NAD(P)H:Quinone Oxidoreductase Gene With Adult Acute Myeloid Leukemia , 2011 .

[2]  L. Tone,et al.  Increased Risk for Acute Lymphoblastic Leukemia in Children with Cytochrome P450 A1(CYP1A1)- and NAD(P)H:Quinone Oxidoreductase 1 (NQO1)-Inherited Gene Variants , 2010, Acta Haematologica.

[3]  F. Zaker,et al.  Methylenetetrahydrofolate Reductase Gene Polymorphisms and Risk of Myeloid Leukemia , 2010 .

[4]  J. Vijayakrishnan,et al.  Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis , 2010, Haematologica.

[5]  C. Scrideli,et al.  Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children , 2009, Environmental and molecular mutagenesis.

[6]  A. Chokkalingam,et al.  NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. , 2008, American journal of epidemiology.

[7]  C. Weinberg,et al.  Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia. , 2007, American journal of epidemiology.

[8]  A. Chokkalingam,et al.  NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. , 2008, American Journal of Epidemiology.

[9]  Bharat B. Aggarwal,et al.  Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-κB, IκBα Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis* , 2006, Journal of Biological Chemistry.

[10]  D. Sahar,et al.  The frequencies of NAD(P)H quinone oxidoreductase (NQO1) variant allele in Israeli ethnic groups and the relationship of NQO1*2 to adult acute myeloid leukemia in Israeli patients. , 2006, Haematologica.

[11]  M. Loriot,et al.  Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[12]  Y. Nakanishi,et al.  NQO1, MPO, and the risk of lung cancer: A HuGE review , 2005, Genetics in Medicine.

[13]  M. Valsecchi,et al.  Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements , 2005, Leukemia.

[14]  M. Eguchi,et al.  The association of a distinctive allele of NAD(P)H:quinone oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. , 2005, Haematologica.

[15]  M. Gallegos-Arreola,et al.  Cytochrome P4501A1 polymorphism is associated with susceptibility to acute lymphoblastic leukemia in adult Mexican patients. , 2004, Blood cells, molecules & diseases.

[16]  A. Abraham,et al.  Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children , 2004, Pediatric blood & cancer.

[17]  R. Aplenc.  Genetic polymorphisms of CYP1A1, CYP2D6, GSTM1, and GSTT1 and susceptibility to acute lymphoblastic leukemia in Indian children , 2004, Pediatric blood & cancer.

[18]  T. Celkan,et al.  NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia , 2004, Pediatric blood & cancer.

[19]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. , 2004, Methods in enzymology.

[20]  Ching-Hon Pui,et al.  Childhood and adolescent lymphoid and myeloid leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[21]  David Siegel,et al.  Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.

[22]  P. Nowell,et al.  Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. , 2002, Blood.

[23]  P. Farabaugh,et al.  Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T. , 2002, Pharmacogenetics.

[24]  H. Norppa,et al.  Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. , 2002, Carcinogenesis.

[25]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Labuda,et al.  Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia , 2002, International journal of cancer.

[27]  M F Greaves,et al.  A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. , 1999, Cancer research.

[28]  R. Larson,et al.  Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. , 1999, Blood.

[29]  J. Lear,et al.  Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. , 1999, Carcinogenesis.

[30]  J. Segura-Aguilar,et al.  Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. , 1999, Free radical biology & medicine.

[31]  八木 国夫.  Pathophysiology of lipid peroxides and related free radicals , 1998 .

[32]  T. Ebert,et al.  Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. , 1997, Pharmacogenetics.

[33]  M. Spitz,et al.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. , 1997, British Journal of Cancer.

[34]  G. Powis,et al.  An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. , 1995, Cancer research.

[35]  M. Greaves,et al.  An infectious etiology for common acute lymphoblastic leukemia in childhood? , 1993, Leukemia.

[36]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[37]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .